• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    6/18/24 12:31:11 PM ET
    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email

    Gainers

    • Mustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 27.95% to $0.22. The company's market cap stands at $3.3 million. The company's, Q4 earnings came out yesterday.
    • Vaxart (NASDAQ:VXRT) shares moved upwards by 27.83% to $0.67. The market value of their outstanding shares is at $118.6 million.
    • Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.92% to $26.86. The company's market cap stands at $1.0 billion.
    • Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.1% to $0.21. The company's market cap stands at $11.6 million.
    • AtriCure (NASDAQ:ATRC) shares rose 16.01% to $23.04. The market value of their outstanding shares is at $1.1 billion.

    Losers

    • DermTech (NASDAQ:DMTK) shares decreased by 59.5% to $0.13 during Tuesday's regular session. The company's market cap stands at $4.7 million.
    • Zentalis Pharma (NASDAQ:ZNTL) shares declined by 35.7% to $5.39. The company's market cap stands at $383.1 million.
    • Anitra (AMEX:AZTR) shares fell 30.21% to $0.16. The market value of their outstanding shares is at $4.6 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) stock decreased by 28.75% to $3.99. The market value of their outstanding shares is at $2.3 million.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares decreased by 27.18% to $2.94. The market value of their outstanding shares is at $548.8 million.
    • Autonomix Medical (NASDAQ:AMIX) stock fell 26.67% to $0.99. The market value of their outstanding shares is at $18.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMIX
    $ATRC
    $AZTR
    $DMTK

    CompanyDatePrice TargetRatingAnalyst
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    3/17/2026$5.00Equal Weight
    Wells Fargo
    AtriCure Inc.
    $ATRC
    2/18/2026Outperform → Perform
    Oppenheimer
    AtriCure Inc.
    $ATRC
    2/11/2026$36.00Overweight → Neutral
    Analyst
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    AtriCure Inc.
    $ATRC
    12/17/2024$40.00Overweight
    Analyst
    Vaxart Inc
    $VXRT
    8/15/2024$4.00Outperform
    Oppenheimer
    Zentalis Pharmaceuticals Inc.
    $ZNTL
    8/12/2024$4.00Underperform → Neutral
    Wedbush
    More analyst ratings

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

    Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer  Demonstration of Cyclin E1 protein overexpression as an indicator for poor prognosis in ovarian cancer patients with real world data  SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 202

    3/17/26 4:30:00 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

    JERUSALEM, March 16, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), today announced that it received a written notification from the Nasdaq Listing Qualifications Department on March 12, 2026 indicating that the Company is not in compliance with the Nasdaq Capital Market's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the American Depositary Shares ("ADSs") was below $1.00 per share for 30 consecutive business days. The notification has no immediate effect on the listing or trading of the ADSs on the Nasdaq Capital Market.In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has

    3/16/26 4:05:00 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement

    BRANFORD, Conn., March 13, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As previously reported, on Octobe

    3/13/26 5:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lo Steven

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/18/26 9:44:44 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Tucker Sean

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/18/26 7:42:42 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Grasman Jeroen Nicolaas

    4 - Vaxart, Inc. (0000072444) (Issuer)

    3/18/26 7:42:17 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo resumed coverage on Zentalis Pharma with a new price target

    Wells Fargo resumed coverage of Zentalis Pharma with a rating of Equal Weight and set a new price target of $5.00

    3/17/26 9:31:05 AM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AtriCure downgraded by Oppenheimer

    Oppenheimer downgraded AtriCure from Outperform to Perform

    2/18/26 7:52:06 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure downgraded by Analyst with a new price target

    Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00

    2/11/26 7:49:25 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    SEC Filings

    View All

    Azitra Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    3/13/26 5:26:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vaxart Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vaxart, Inc. (0000072444) (Filer)

    3/12/26 4:11:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    3/5/26 4:36:04 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Walters Group bought $7,751,968 worth of shares (6,459,973 units at $1.20) (SEC Form 4)

    4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

    1/8/26 4:57:05 PM ET
    $ZNTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Leadership Updates

    Live Leadership Updates

    View All

    Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

    Believe Elevating W. Mark Watson – who Received only 56% of Votes Cast at Last Annual Meeting – to Lead Independent Director Fails to Deliver Real Reform Reiterate Intent to Vote Against Reverse Stock Split at September 19th Special Meeting ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Mark Silverberg, DDS, MD, Matthew M. Wallace, MD and David Whitney (collectively, the "Concerned Vaxart Stockholders"), who collectively beneficially own more than 2.6 million shares of Vaxart, Inc. (OTC:VXRT) ("Vaxart" or the "Company"), today issued a statement in response to the Company's app

    9/18/25 9:00:00 AM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Appoints W. Mark Watson as Lead Independent Director

    In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders Vaxart encourages all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced today that W. Mark Watson has been appointed Lead Independent Director. Mr. Watson is a Certified Public Accountant with over 50 years of experien

    9/17/25 4:05:01 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025. "It has been a profound privilege to serve as Vaxart's Chairman and be a part of this incredible Company's journey for so many years," said Mr. Finney. "I am immensely proud of what w

    9/2/25 4:30:52 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Financials

    Live finance-specific insights

    View All

    Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

    Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin

    3/12/26 4:05:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2025, and host a corporate update conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha's website at ir.tayshagtx.com. An archived replay of the webcast will be available on

    3/12/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vaxart to Host Upcoming Conference Calls

    Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul

    3/3/26 4:01:00 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMIX
    $ATRC
    $AZTR
    $DMTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    12/3/24 6:17:58 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Autonomix Medical Inc.

    SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

    11/27/24 10:15:18 AM ET
    $AMIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Taysha Gene Therapies Inc.

    SC 13G/A - Taysha Gene Therapies, Inc. (0001806310) (Subject)

    11/14/24 5:51:11 PM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care